- Home
- GMAB vs AZPN Comparison
GMAB vs AZPN Comparison
Compare GMAB & AZPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- AZPN
- Stock Information
- Founded
- GMAB 1999
- AZPN 1981
- Country
- GMAB Denmark
- AZPN United States
- Employees
- GMAB N/A
- AZPN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- AZPN EDP Services
- Sector
- GMAB Health Care
- AZPN Technology
- Exchange
- GMAB Nasdaq
- AZPN Nasdaq
- Market Cap
- GMAB 15.0B
- AZPN 15.9B
- IPO Year
- GMAB N/A
- AZPN 1994
- Fundamental
- Price
- GMAB $21.80
- AZPN $255.55
- Analyst Decision
- GMAB Buy
- AZPN Strong Buy
- Analyst Count
- GMAB 8
- AZPN 5
- Target Price
- GMAB $43.00
- AZPN $258.00
- AVG Volume (30 Days)
- GMAB 1.1M
- AZPN 426.7K
- Earning Date
- GMAB 02-12-2025
- AZPN 02-04-2025
- Dividend Yield
- GMAB N/A
- AZPN 0.21%
- EPS Growth
- GMAB 14.35
- AZPN N/A
- EPS
- GMAB 10.80
- AZPN N/A
- Revenue
- GMAB $2,967,926,227.00
- AZPN $1,094,051,000.00
- Revenue This Year
- GMAB $32.03
- AZPN $7.85
- Revenue Next Year
- GMAB $16.97
- AZPN $7.57
- P/E Ratio
- GMAB $19.02
- AZPN N/A
- Revenue Growth
- GMAB 17.75
- AZPN 4.93
- 52 Week Low
- GMAB $19.85
- AZPN $171.25
- 52 Week High
- GMAB $31.88
- AZPN $255.62
- Technical
- Relative Strength Index (RSI)
- GMAB 54.72
- AZPN 64.70
- Support Level
- GMAB $19.89
- AZPN $249.25
- Resistance Level
- GMAB $21.26
- AZPN $252.05
- Average True Range (ATR)
- GMAB 0.42
- AZPN 2.35
- MACD
- GMAB 0.02
- AZPN 0.17
- Stochastic Oscillator
- GMAB 80.08
- AZPN 94.11
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About AZPN Aspen Technology Inc.
Aspen Technology is a global leader in asset optimization software, enabling customers within capital-intensive industries to design, operate and maintain their functions to meet their profitability, safety, and sustainability goals. The heritage business of AspenTech was founded in 1981 and provides software solutions purposed to optimize engineering, manufacturing, and supply chain and asset management functions. In 2021, Emerson Electric traded over $6 billion in cash and its Open Systems International (digital grid management) and subsurface science and engineering businesses for 55% of AspenTech's shares. The new AspenTech is the combination of heritage Aspen, OSI, and SSE and serves more than 3,000 customers across 40 countries.